Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.
Insider Monkey

Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...
Blockonomi

Structure Therapeutics (GPCR) Stock Jumps 10% After Breakthrough GLP-1 Weight Loss Data

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.
Insider Monkey

Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts?

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

Assessing Structure Therapeutics (GPCR) Valuation After Sharp Swings And A Strong 1 Year Return

Structure Therapeutics (GPCR) has drawn attention after recent share price swings, including a month return of a 27.7% decline and a past 3 months gain of 80.8%, prompting investors to reassess its ...